Rafferty Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.59M | Sell |
44,842
-17,637
| -28% | -$1.45M | 0.01% | 483 |
|
|
2025
Q4 | $5.33M | Sell |
62,479
-2,694
| -4% | -$221K | 0.02% | 417 |
|
|
2025
Q3 | $5.07M | Buy |
65,173
+3,163
| +5% | +$247K | 0.02% | 425 |
|
|
2025
Q2 | $4.85M | Buy |
62,010
+7,399
| +14% | +$552K | 0.02% | 406 |
|
|
2025
Q1 | $3.96M | Sell |
54,611
-12,276
| -18% | -$879K | 0.02% | 419 |
|
|
2024
Q4 | $4.95M | Buy |
66,887
+5,788
| +9% | +$405K | 0.02% | 419 |
|
|
2024
Q3 | $4.03M | Sell |
61,099
-4,434
| -7% | -$322K | 0.01% | 464 |
|
|
2024
Q2 | $6.05M | Buy |
65,533
+2,940
| +5% | +$260K | 0.02% | 378 |
|
|
2024
Q1 | $5.98M | Buy |
62,593
+849
| +1% | +$71.3K | 0.02% | 432 |
|
|
2023
Q4 | $4.71M | Sell |
61,744
-1,685
| -3% | -$117K | 0.02% | 454 |
|
|
2023
Q3 | $4.39M | Buy |
63,429
+4,785
| +8% | +$385K | 0.03% | 411 |
|
|
2023
Q2 | $5.53M | Buy |
58,644
+3,330
| +6% | +$289K | 0.03% | 389 |
|
|
2023
Q1 | $4.58M | Buy |
55,314
+2,131
| +4% | +$168K | 0.03% | 401 |
|
|
2022
Q4 | $3.97M | Buy |
53,183
+20,054
| +61% | +$1.55M | 0.03% | 428 |
|
|
2022
Q3 | $2.74M | Buy |
33,129
+18,044
| +120% | +$1.74M | 0.03% | 440 |
|
|
2022
Q2 | $1.43M | Sell |
15,085
-3,998
| -21% | -$414K | 0.01% | 550 |
|
|
2022
Q1 | $2.25M | Sell |
19,083
-1,901
| -9% | -$213K | 0.01% | 568 |
|
|
2021
Q4 | $2.72M | Buy |
20,984
+1,110
| +6% | +$129K | 0.01% | 563 |
|
|
2021
Q3 | $2.25M | Buy |
19,874
+6,076
| +44% | +$694K | 0.02% | 602 |
|
|
2021
Q2 | $1.43M | Buy |
13,798
+908
| +7% | +$85.6K | 0.01% | 778 |
|
|
2021
Q1 | $1.08M | Buy |
12,890
+962
| +8% | +$81.3K | 0.01% | 756 |
|
|
2020
Q4 | $1.09M | Sell |
11,928
-30,655
| -72% | -$2.54M | 0.01% | 479 |
|
|
2020
Q3 | $3.4M | Sell |
42,583
-10,281
| -19% | -$802K | 0.04% | 247 |
|
|
2020
Q2 | $3.65M | Sell |
52,864
-5,201
| -9% | -$370K | 0.05% | 227 |
|
|
2020
Q1 | $3.65M | Buy |
58,065
+41,172
| +244% | +$2.97M | 0.15% | 79 |
|
|
2019
Q4 | $1.31M | Buy |
+16,893
| New | +$1.32M | 0.02% | 484 |
|
|
2017
Q4 | – | Sell |
-20,238
| Closed | -$737K | – | 712 |
|
|
2017
Q3 | $737K | Buy |
+20,238
| New | +$772K | 0.02% | 466 |
|
|
2017
Q2 | – | Sell |
-28,569
| Closed | -$896K | – | 565 |
|
|
2017
Q1 | $896K | Buy |
+28,569
| New | +$894K | 0.02% | 386 |
|
|
2016
Q4 | – | Sell |
-16,173
| Closed | -$650K | – | 473 |
|
|
2016
Q3 | $650K | Sell |
16,173
-1,395
| -8% | -$52.5K | 0.02% | 292 |
|
|
2016
Q2 | $584K | Sell |
17,568
-35,634
| -67% | -$1.22M | 0.04% | 335 |
|
|
2016
Q1 | $1.56M | Buy |
+53,202
| New | +$1.47M | 0.09% | 174 |
|
|
2014
Q3 | – | Sell |
-19,800
| Closed | -$283K | – | 375 |
|
|
2014
Q2 | $283K | Buy |
+19,800
| New | +$268K | 0.05% | 248 |
|
Other funds holding EW
VCM
VPM
Rafferty Asset Management's EW Position: Q1 2026 in Review
Rafferty Asset Management reduced its Edwards Lifesciences (EW) stake by 28% in Q1 2026, selling an estimated $1.45M and leaving 44,842 shares worth $3.59M. The position accounts for 0.01% of the portfolio, ranked #483.
Rafferty Asset Management first reported a position in EW in Q2 2014 and has held it in 32 quarters since. The position peaked at $6.05M in Q2 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Rafferty Asset Management held 44,842 shares of Edwards Lifesciences worth $3.59M as of Q1 2026.
- Rafferty Asset Management sold 17,637 Edwards Lifesciences shares in Q1 2026, an estimated $1.45M.
- Edwards Lifesciences made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #483 holding.
- Rafferty Asset Management first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 32 quarters since.
- Rafferty Asset Management's Edwards Lifesciences position peaked at $6.05M in Q2 2024.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.